NCT06195228RecruitingPhase 4
A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer
Source: ClinicalTrials.gov · Last updated 14 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a retrospective and prospective real-world clinical study of molecular typing in the treatment of advanced thyroid cancer. The retrospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 participated hospitals from January 2020 to December 2023 were retrieved. The number of previous treatment lines was not limited. Patients who met the inclusion criteria were screened according to the inclusion and exclusion criteria. Demographic information, clinical characteristics, tumor treatment history, medication regimen, adverse reactions, molecular test results, survival follow-up results and other data were collected. The prospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 Chinese hospitals from January 2024 to April 2027 were enrolled.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 800 (estimated)
- First submitted
- 23 Dec 2023
- Start date
- 1 Jan 2020
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Fudan University
- Diseases
- Thyroid cancer, Childhood cancers
- NCT number
- NCT06195228
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 800
- From 1 Jan 2020 to the primary completion date, 31 Dec 2026
- 8 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who are participating in clinical trials of other drugs;
Other
- There is evidence that the patients are pregnant or lactating;
- Other situations that are not suitable for inclusion in this study.
Who the study is looking for
- Patients volunteered to participate in this study and signed informed consent;
- Each center can be enrolled in patients who meet the age of their own practice range, regardless of gender ;
- Histologically diagnosed locally advanced or recurrent / metastatic thyroid cancer that cannot undergo radical surgery meets one of the following requirements:
- Radioiodine-refractory differentiated thyroid cancer (RAIR-DTC);
- Differentiated thyroid carcinoma not suitable for iodine therapy;
- Medullary thyroid carcinoma (MTC);
- poorly differentiated thyroid cancer (PDTC) or anaplastic thyroid cancer (ATC);
- Thyroid-related pathogenic or therapeutic target gene detection was performed before enrollment.
Sex: All · Does not accept healthy volunteers
Sites (8)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking Union Medical College Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
| Fujian Cancer Hospital Coordinator of this site? Confirm its status | Fuzhou | China | Recruiting |
| Zhejiang Cancer Hospital Coordinator of this site? Confirm its status | Hangzhou | China | Recruiting |
| Caixia Liu Coordinator of this site? Confirm its status | Hohhot | China | Recruiting |
| Fudan University Shanghai Cancer Center Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
| Shanxi Cancer Hospital Coordinator of this site? Confirm its status | Shanxi | China | Recruiting |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Coordinator of this site? Confirm its status | Wuhan | China | Recruiting |
| Henan Cancer Hospital Coordinator of this site? Confirm its status | Zhengzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.